Evaluation of SPN-812 ER Low Dose in Children With ADHD
Phase of Trial: Phase III
Latest Information Update: 08 May 2018
At a glance
- Drugs Viloxazine (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Registrational; Therapeutic Use
- Sponsors Supernus Pharmaceuticals
- 08 May 2018 event According to a Supernus Pharmaceuticals media release, approximately 61% of overall enrollment in the SPN-812 program has been completed. This program consists of four trials: two of which are pediatric trials ( CTP 287730 and CTP 287729 ) and two of which are adolescent trials ( CTP 287727 and CTP 282575 ).
- 27 Feb 2018 According to a Supernus Pharmaceuticals media release, the Company expects to continue enrollment in this trial through mid-2018 and to have data available by the first quarter of 2019.
- 06 Nov 2017 Status changed from not yet recruiting to recruiting, according to a Supernus Pharmaceuticals media release.